期刊
ALLERGY
卷 77, 期 7, 页码 1961-1990出版社
WILEY
DOI: 10.1111/all.15214
关键词
C1 inhibitor; DELPHI; disease control; guideline; hereditary angioedema; management
资金
- WAO
- EAACI
- GA2LEN/HAEi network of Angioedema Centers of Reference and Excellence (ACARE)
The revision and update of the guideline on the diagnosis and management of hereditary angioedema (HAE) provides up-to-date guidance for physicians and their patients. It aims to help make rational decisions in the management of HAE, including diagnostics, treatments, goals of treatment, management for special patient groups, and disease monitoring.
Hereditary angioedema (HAE) is a rare and disabling disease for which early diagnosis and effective therapy are critical. This revision and update of the global WAO/EAACI guideline on the diagnosis and management of HAE provides up-to-date guidance for the management of HAE. For this update and revision of the guideline, an international panel of experts reviewed the existing evidence, developed 28 recommendations, and established consensus by an online DELPHI process. The goal of these recommendations and guideline is to help physicians and their patients in making rational decisions in the management of HAE with deficient C1 inhibitor (type 1) and HAE with dysfunctional C1 inhibitor (type 2), by providing guidance on common and important clinical issues, such as: (1) How should HAE be diagnosed? (2) When should HAE patients receive prophylactic on top of on-demand treatment and what treatments should be used? (3) What are the goals of treatment? (4) Should HAE management be different for special HAE patient groups such as children or pregnant/breast-feeding women? and (5) How should HAE patients monitor their disease activity, impact, and control? It is also the intention of this guideline to help establish global standards for the management of HAE and to encourage and facilitate the use of recommended diagnostics and therapies for all patients.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据